A multi-year $900,000 grant titled “A Personalized Treatment Strategy for Parkinson’s Disease”. This grant will help to explore the role and impact of mitochondrial protein Mirol both as a molecular signature and as a drug target for Parkinson’s disease.
Parkinson’s disease (PD) is the second most common movement disorder, afflicting the aging population. Currently, there is no disease-modifying therapy for PD due to the lack of the understanding of disease mechanisms. In addition, there are no reliable biomarkers for aiding in diagnosis and monitoring drug efficacy. These challenges limit moving experimental therapies from bench to bedside. In this proposal, the Stanford team will couple drug discovery and developing companion diagnostic tool to address these challenges with the hope to find a better treatment for PD.
